elF2 alpha (EIF2S1) Mouse Monoclonal Antibody [Clone ID: 2E4-F5-E7]

CAT#: TA346937S

Mouse Monoclonal eIF2a Antibody

Size: 20 ul 100 ul



Need it in bulk or conjugated?
Get a free quote

CNY 800.00


货期*
2周

规格
    • 20 ul

Product images

经常一起买 (3)
beta Actin Mouse Monoclonal Antibody, Clone OTI1, Loading Control
    • 30 ul

CNY 300.00
CNY 1,430.00


Recombinant protein of human eukaryotic translation initiation factor 2, subunit 1 alpha, 35kDa (EIF2S1), 20 µg
    • 20 ug

CNY 2,900.00
CNY 6,650.00


Transient overexpression lysate of eukaryotic translation initiation factor 2, subunit 1 alpha, 35kDa (EIF2S1)
    • 100 ug

CNY 3,080.00

Specifications

Product Data
Clone Name 2E4-F5-E7
Applications IF, IP, WB
Recommend Dilution WB: 1:1000
Reactivity Human, Rat
Host Mouse
Clonality Monoclonal
Immunogen The immunogen for EIF2S1 antibody: purified recombinant human eIF2a protein fragments expressed in E.coli.
Formulation PBS(pH 7.4) containing with 0.03% Proclin300 and 50% glycerol.
Purification Affinity purified
Conjugation Unconjugated
Storage Condition Store at -20°C as received.
Gene Name eukaryotic translation initiation factor 2 subunit alpha
Background The translation initiation factor EIF2 catalyzes the first regulated step of protein synthesis initiation, promoting the binding of the initiator tRNA to 40S ribosomal subunits. Binding occurs as a ternary complex of methionyl-tRNA, EIF2, and GTP. EIF2 is composed of 3 nonidentical subunits, the 36-kD EIF2-alpha subunit (EIF2S1), the 38-kD EIF2-beta subunit (EIF2S2; MIM 603908), and the 52-kD EIF2-gamma subunit (EIF2S3; MIM 300161). The rate of formation of the ternary complex is modulated by the phosphorylation state of EIF2-alpha (Ernst et al., 1987 [PubMed 2948954]).
Synonyms EIF-2; EIF-2A; EIF-2alpha; EIF2; EIF2A
Reference Data
*Delivery time may vary from web posted schedule. Occasional delays may occur due to unforeseen complexities in the preparation of your product. International customers may expect an additional 1-2 weeks in shipping.
Customer Reviews 
Loading...